GUFICBIO2024-10-012024-12-31 GUFICBIO2024-10-012024-12-31 GUFICBIO2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member GUFICBIO2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member GUFICBIO2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 509079 GUFICBIO NOTLISTED Gufic Biosciences Limited Equity 2024-04-01 2025-03-31 2025-02-14 2025-02-07 INR Lakhs Third quarter 15:14:00 16:11:00 2025-02-14 2025-02-14 Not applicable Single segment The Company's business activity falls within a single operating segment i.e. Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 2077939000.00 18636000.00 2096575000.00 735869000.00 155495000.00 50292000.00 339577000.00 49091000.00 46182000.00 457464000.00 1833970000.00 262605000.00 0.00 262605000.00 39500000.00 30054000.00 69554000.00 0.00 193051000.00 0.00 0.00 0.00 0.00 193051000.00 0.00 193051000.00 0.00 -1000.00 0.00 0.00 100278000.00 1 1.93 1.93 0.00 0.00 1.93 1.93 0.00 0.00 0.00 1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. 2. The above results for the quarter ended December 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 14, 2025. The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2024. 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. 4. The Company has incorporated Gufic UK Limited ( GUL ) in United Kingdom on March 15, 2022, Gufic Ireland Limited ( GIL ) in Ireland on March 02, 2023, Veira Life FZE ( VLF ) in Dubai, UAE on March 25, 2024 and Gufic Prime Private Limited (“GPPL”) in India on November 18, 2023, with the intention of making GUL, GIL and VLF its Wholly Owned Subsidiaries and GPPL as its Subsidiary Company. As of December 31, 2024, neither investment have been made in GIL and VLF nor they have begun their business operations. Consequently, there was no need to consolidate the accounts of GIL and VLF with the Company. However, the Company has invested in GUL on September 13, 2023 and in GPPL on April 25, 2024 by subscribing to its shares. Consequently, the consolidated financial results for the quarter and nine months ended December 31, 2024, have been prepared by the Company considering the financials of GUL and GPPL. 5. The equity shares and basic/diluted earnings per share for the comparative period (quarter and period ended December 31, 2023) has been presented in accordance with Ind AS - 33-Earning per share. 6. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 6147858000.00 32320000.00 6180178000.00 2212886000.00 445654000.00 191795000.00 914761000.00 147118000.00 132212000.00 1299567000.00 5343993000.00 836185000.00 0.00 836185000.00 184500000.00 32393000.00 216893000.00 0.00 619292000.00 0.00 0.00 0.00 0.00 619292000.00 0.00 619292000.00 0.00 -8000.00 0.00 0.00 100278000.00 1 6.18 6.18 0.00 0.00 6.18 6.18 0.00 0.00 0.00 Other Expenses 457464000.00 Other Expenses 1299567000.00